Skip to main content

Home

Latest news

Browse topics

Lupus
Rheumatoid arthritis
Spondyloarthropathies
COVID-19
Browse all topics

In focus

Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings

Conferences

ACR Convergence 2022
EULAR 2022 Congress

About us

Medicine Matters Rheumatology
EXTENDED SEARCH
Log in

Regulatory updates

Regulatory updates

05-02-2021 | Rheumatoid arthritis | News

FDA issues safety alert on risk for CV events, cancer with tofacitinib

18-12-2020 | Upadacitinib | News

EMA gives nod to upadacitinib for psoriatic arthritis, ankylosing spondylitis

20-11-2020 | COVID-19 | News

FDA authorizes baricitinib combination for COVID-19

21-08-2019 | Rheumatoid arthritis | News

Upadacitinib gains FDA approval for RA

29-07-2019 | Rheumatoid arthritis | News

FDA adds boxed warnings to tofacitinib label

14-05-2018 | Psoriatic arthritis | News

Tofacitinib given go-ahead for PsA